Table 1 Baseline characteristics according to KRAS mutation status

Age, year, Median (range)

55.8 (25–77)

58.8 (25–77)

55.5 (29–77)

0.565

≥65 years

17 (21 %)

12 (24 %)

5 (16 %)

0.423

Sex

0.867

 Male

44 (54 %)

27 (53 %)

17 (55 %)

 Female

38 (46 %)

24 (47 %)

14 (45 %)

Location

0.246

 Colon

54 (66 %)

36 (71 %)

18 (58 %)

 Rectum

28 (34 %)

15 (29 %)

13 (42 %)

Neoadjuvant Chemotherapy

21 (26 %)

11 (22 %)

10 (32 %)

0.282

Resection site

0.039

 Liver

57 (69 %)

39 (76 %)

18 (58 %)

 Lung

13 (16 %)

4 (8 %)

9 (29 %)

 Others (ovary, bladder)

12 (15 %)

8 (16 %)

4 (13 %)

Tumor grade

0.432

 Well

10 (12 %)

7 (14 %)

3 (10 %)

 Moderate/Poor

72 (78 %)

44 (86 %)

28 (90 %)

T stage

0.265

 T1

1 (1 %)

1 (2 %)

0 (0 %)

 T2

2 (2 %)

2 (4 %)

0 (0 %)

 T3

47 (57 %)

30 (59 %)

17 (55 %)

 T4

30 (37 %)

18 (35 %)

12 (39 %)

 Tx

2 (2 %)

0 (0 %)

2 (6 %)

N stage

0.824

 N0

12 (15 %)

8 (16 %)

4 (13 %)

 N1

31 (38 %)

18 (35 %)

13 (42 %)

 N2

39 (47 %)

25 (49 %)

14 (45 %)

1st Adjuvant Chemo-Regimen

0.923

 Oxaliplatin-based

70 (86 %)

44 (86 %)

26 (84 %)

 Irinotecan-based

10 (12 %)

6 (12 %)

4 (13 %)

 Only 5-FU

2 (2 %)

1 (2 %)

1 (3 %)

Use of Cetuximab at 1st post-operative chemotherapy

4 (5 %)

4 (8 %)

0 (0 %)

NA

Use of Becavizumab at 1st post-operativechemotherapy

13 (16 %)

6 (12 %)

7 (23 %)

0.194

Ever use of Cetuximab

16 (20 %)

16 (31 %)

0 (0 %)

NA

Ever use of Bevacizumab

23 (28 %)

10 (20 %)

13 (42 %)

0.029

Recurrence pattern (n = 57)

0.616

 Primary site

3 (5 %)

1 (2 %)

2 (8 %)

 Metastasectomy site

27 (47 %)

15 (46 %)

12 (50 %)

 New distant sites

27 (47 %)

17 (52 %)

10 (42 %)

Duration of follow up month, median (range)

25 (4–74)

25 (4–74)

34 (9–63)

0.763